
EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
23 julio 2010
Genomica SAU en el 2010 AACC Annual Meeting and Clinical Lab Expo. Del 25 al 29 Julio en Anaheim ( California ) .

GENOMICA S.A.U. ( Zeltia Group ) develops, produces and commercializes applications for differential molecular in vitro diagnosis based on the amplification and detection of the genetic material on an innovative platform CLINICAL ARRAY TECHNOLOGY:
*.- CLART®. CLART®HPV: 35 human Papillomavirus genotypes .
*.- CLART®Metabone: bone metabolic disorders .
*.- CLART®ENTHERPEX: 8 Herpesvirus and enterovirus.
*.- CLART®PneumoVir: 17 relevant respiratory viruses.
Suscribirse a:
Entradas (Atom)